Terminated PHASE2 INTERVENTIONAL 2-arm NCT00450242

5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis

Use of 5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis

Sponsor: University of North Carolina, Chapel Hill

Interventions 5% topical lidocaine ointment Placebo cream

Updated 9 times since 2017 Last updated: Jun 12, 2012 Started: Dec 31, 2006 Primary completion: Jan 31, 2009 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

lack of funding

Other terminated trials from University of North Carolina, Chapel Hill

See all terminations from University of North Carolina, Chapel Hill

Listed as NCT00450242, this PHASE2 trial focuses on Vulvar Vestibulitis and remains terminated or withdrawn. Sponsored by University of North Carolina, Chapel Hill, it has been updated 9 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Dec 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of North Carolina, Chapel Hill

Data source: University of North Carolina, Chapel Hill

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chapel Hill, United States